Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (MNMD)
NASDAQ:MNMD
MNMD Stock Chart & Stats
$15.02
-$0.97(-11.96%)
At close: 4:00 PM EST
$15.02
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$4.70 - $15.29
Previous CloseN/A
Volume779.86K
Average Volume (3M)2.00M
Market Cap
$1.48B
Enterprise Value$992.63M
Total Cash (Recent Filing)$209.07M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 05, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding98,509,280
10 Day Avg. Volume2,108,466
30 Day Avg. Volume1,996,920
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.08
Forecast
1Y Price Target
$30.80Price Target Upside105.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical De-riskingAnalyst views multiple late-stage trials for the lead candidate as de-risked by strong earlier-stage efficacy, increasing the probability that positive Phase III outcomes will validate the program.
Market Opportunity And Differentiated ProfileAnalyst highlights that a differentiated clinical profile with indications of more durable benefits and early efficacy positions the asset to capture unmet patient need and build rapid market awareness.
Strategic RepositioningCompany rebranding combined with a clear pipeline plan and an upcoming analyst day signals focused management execution and clearer communication of the path to commercialization.
Bears Say
Liquidity And Dilution RiskAnalyst warns that high annual cash burn relative to available resources raises the likelihood of future fundraising, which could dilute shareholders and disrupt development timelines.
Regulatory UncertaintyAnalyst cautions that the lead compound's relation to LSD, a Schedule I controlled substance, creates unique regulatory and clinical hurdles that could complicate approvals and limit market access.
Mind Medicine News
MNMD FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was $4.70 and its highest was $15.29 in the past 12 months.
What is Mind Medicine’s market cap?
Mind Medicine’s market cap is $1.48B.
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Mar 05, 2026 which is in 48 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Nov 06, 2025. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.501 by -$0.279.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -0.5.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 98,509,280 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.501. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in MNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mind Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.80 (105.06% Upside)
$30.80 (105.06% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 21.3%
Last 30 Days ▲ 21.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.51%
12-Months-Change
Fundamentals
Return on Equity
-85.59%
Trailing 12-Months
Asset Growth
-25.91%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
MNMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a largely positive outlook for Mind Medicine (MindMed) Inc., with significant achievements in clinical trial progress, financial strengthening through capital raise, and promising advancements in their pipeline. However, increased expenses and net loss reflect some financial challenges.View all MNMD earnings summariesMNMD Stock 12 Month Forecast
Average Price Target
$30.80
▲(105.06% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.68% Insiders
5.46% Mutual Funds
0.04% Other Institutional Investors
83.54% Public Companies and Individual Investors